Meril Life Sciences Pvt. Ltd., commonly referred to as Meril, is a leading medical technology company headquartered in India. Established in 2006, Meril has made significant strides in the healthcare sector, focusing on innovative solutions in the fields of interventional cardiology, orthopaedics, and endoscopy. With a strong presence in both domestic and international markets, the company operates extensively across Asia, Europe, and the Americas. Meril is renowned for its cutting-edge products, including bioresorbable stents and advanced surgical instruments, which are designed to enhance patient outcomes and streamline medical procedures. The company’s commitment to research and development has positioned it as a key player in the medical device industry, earning accolades for its contributions to healthcare innovation. With a robust portfolio and a dedication to quality, Meril Life Sciences continues to set benchmarks in the medical technology landscape.
How does Meril Life Sciences Pvt. Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Meril Life Sciences Pvt. Ltd's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Meril Life Sciences Pvt. Ltd, headquartered in India, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary and may inherit climate commitments and data from its parent organisation, but no specific details are available regarding these cascaded emissions or targets. In terms of climate commitments, Meril Life Sciences has not outlined any reduction targets or initiatives, such as those associated with the Science Based Targets initiative (SBTi) or other industry-standard frameworks. The lack of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As a part of the broader industry context, it is essential for companies like Meril Life Sciences to establish clear emissions reduction targets and engage in climate action to align with global sustainability goals. Without specific data or commitments, the company's current climate impact remains unclear.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Meril Life Sciences Pvt. Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
